{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:16:12Z","timestamp":1792790172124,"version":"4.5.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To retrospectively evaluate the 1-year efficacy and safety of single-agent of omidenepag isopropyl in patients with normal-tension glaucoma (NTG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>One hundred patients (100 eyes) newly administered omidenepag isopropyl were enrolled. Intraocular pressure (IOP) was compared at baseline and 3, 6, 9, and 12 months after administration. The mean deviation values at baseline and 12 months measured using the Humphrey visual field test (30-2 Swedish Interactive Threshold Algorithm standard) were compared. Adverse reactions and dropouts were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      IOP significantly decreased from 15.5\u2009\u00b1\u20092.7\u2009mmHg at baseline to 13.3\u2009\u00b1\u20092.5\u2009mmHg after 3 months, 13.7\u2009\u00b1\u20092.3\u2009mmHg after 6 months, 13.9\u2009\u00b1\u20092.4\u2009mmHg after 9 months, and 13.7\u2009\u00b1\u20092.3\u2009mmHg after 12 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). There was no significant difference in the mean deviation values at baseline (\u22123.66\u2009\u00b1\u20093.49 dB) and after 12 months (\u22123.41\u2009\u00b1\u20093.80 dB). Adverse reactions occurred in 9 patients (9.0%): conjunctival hyperemia (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20096), eye pain (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091), iritis (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091), and blepharitis (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20091). Twenty-one patients (21.0%) discontinued administration because of changes in medication (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20097), interruption of visits (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20095), adverse reactions (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u20094), and others.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>After administering omidenepag isopropyl, the IOP in patients with NTG decreased within 1 year, visual fields were maintained, and safety was satisfactory. Omidenepag isopropyl can be used as the first-line medication for patients with NTG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2021.0122","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T15:54:15Z","timestamp":1653494055000},"page":"354-358","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma"],"prefix":"10.1177","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-0221","authenticated-orcid":false,"given":"Kenji","family":"Inoue","sequence":"first","affiliation":[{"name":"Inouye Eye Hospital, Chiyoda-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Shiokawa","sequence":"additional","affiliation":[{"name":"Inouye Eye Hospital, Chiyoda-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Kunimatsu-Sanuki","sequence":"additional","affiliation":[{"name":"Nishikasai Inouye Eye Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norie","family":"Nozaki","sequence":"additional","affiliation":[{"name":"Omiya Inouye Eye Clinic, Saitama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Sapporo Inouye Eye Clinic, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Toho University Ohashi Medical Center, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goji","family":"Tomita","sequence":"additional","affiliation":[{"name":"Inouye Eye Hospital, Chiyoda-ku, Tokyo, Japan."},{"name":"Department of Ophthalmology, Toho University Ohashi Medical Center, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00272-4"},{"key":"e_1_3_3_3_2","first-page":"429","article-title":"The advanced glaucoma intervention study (AGIS): 7","volume":"130","author":"The AGIS investigators","year":"2000","unstructured":"The AGIS investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130:429\u2013440, 2000.","journal-title":"The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol"},{"key":"e_1_3_3_4_2","first-page":"5","article-title":"The Japan Glaucoma Society Guidelines for Glaucoma","volume":"122","author":"The Japan Glaucoma Society","year":"2018","unstructured":"The Japan Glaucoma Society. The Japan Glaucoma Society Guidelines for Glaucoma. 4th ed. Nippon Ganka Gakkai Zasshi. 122:5\u201353, 2018.","journal-title":"4th ed. Nippon Ganka Gakkai Zasshi"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2012.195"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31824d8d7c"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000001221"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.06.003"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-021-00868-y"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000001836"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-020-00748-x"},{"key":"e_1_3_3_12_2","first-page":"1641","article-title":"The prevalence of primary open-angle glaucoma in Japanese: The Tajimi Study","volume":"111","author":"Iwase A.","year":"2004","unstructured":"Iwase A., , Suzuki Y., , Araie M., et al. The prevalence of primary open-angle glaucoma in Japanese: The Tajimi Study. Ophthalmology. 111:1641\u20131648, 2004.","journal-title":"Ophthalmology"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S271789"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780110508"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2017.0146"},{"key":"e_1_3_3_16_2","first-page":"1475","article-title":"Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues","volume":"43","author":"Schl\u00f6tzer-Schrehardt U.","year":"2002","unstructured":"Schl\u00f6tzer-Schrehardt U., , Zenkel M., , and N\u00fcsing R.M. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest. Ophthalmol. Vis. Sci. 43:1475\u20131487, 2002.","journal-title":"Invest. Ophthalmol. Vis. Sci"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.12.011"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122717"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2005.19.4.297"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-008-0617-8"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S33816"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S46340"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S60538"},{"key":"e_1_3_3_24_2","first-page":"1209","article-title":"Long-term efficacy and safety of 0.03% bimatoprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension","volume":"28","author":"Araie M.","year":"2011","unstructured":"Araie M., , and Kitazawa Y. Long-term efficacy and safety of 0.03% bimatoprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension. Atarashii Ganka. 28:1209\u20131215, 2011.","journal-title":"Atarashii Ganka"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2021.0122","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0122","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:54Z","timestamp":1777646694000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2021.0122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,6,1]]}},"alternative-id":["10.1089\/jop.2021.0122"],"URL":"https:\/\/doi.org\/10.1089\/jop.2021.0122","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}